Skip to main content

Table 1 Summary of in vitro dormancy models classified by cancer/cell type and mode of dormancy induction with associated metrics used to determine dormancy status

From: Engineered In Vitro Models of Tumor Dormancy and Reactivation

Cancer/Cell Type Mode of Dormancy Induction Metrics Analyzed
Breast Cancer
- MDA-MB-231 [43, 59, 82, 88, 91, 93, 96, 98, 106, 116, 118,119,120, 127, 128, 132, 135,136,137, 156, 179]
- MDA-MB-231BRMS1 [139]
- MCF-7 [43, 44, 59, 82, 89, 93, 98, 118, 128, 132, 134,135,136,137, 139, 176]
- T47D [95, 121, 133, 135, 138, 177, 179, 181]
- MDA-MB-435 [58, 176]
- MDA-MB-468 [133]
- MDA-MB-453 [58]
- ZR-75-1 [58]
- SUM149 [58]
- SUM159 [58, 148]
- BT474 [58]
- D2.0R [162, 163, 196]
- 4T1 [176]
ECM-Induced
- Matrix Stiffness/Physical Confinement [87,88,89,90, 92]
- Matrix Composition/ Architecture [92, 97, 105]
- Integrin Engagement [135, 137, 138, 162, 163, 196]
Cell Signaling-Induced
- Endothelial Cells [42, 58, 81, 105, 119]
- Hepatocytes/NPCs [81, 105, 119]
- MSCs [42, 58, 117, 122, 179]
- Fibroblasts [42, 58, 120]
- Osteoblasts [58, 139]
- Exosomes/EVs [121, 122]
Biochemical-Induced
- Hypoxia [128, 129, 133]
- FGF-2 [135,136,137,138, 140, 181]
- Thrombospondin [42]
Drug-Induced
- Doxorubicin [81, 148]
- Docetaxel [148]
- Carboplatin [95]
- Proliferation [42, 58, 81, 87, 88, 95, 105, 117, 119, 129, 148, 163, 172]
- Cell Cycle Analysis [95, 117, 120, 121, 179]
- Metabolic Activity [88, 89, 95, 119, 133]
- Viability [87,88,89,90, 95, 120, 181]
- Morphology [43, 91, 93, 98, 119, 127, 138, 139, 162, 177, 196]
- Gene/Protein Expression [42, 81, 95, 105, 117, 119, 120, 133, 135,136,137,138, 140, 162, 172, 196]
- Invasion/Motility [42, 87, 95, 97]
- Chemoresistance [89, 128, 172, 177]
- Stem Cell Expression [95, 117, 122]
Prostate Cancer
- PC-3 [117, 118, 120, 176]
- DU145 [148, 176, 177]
- C4-2B [128]
- LnCAP [88]
ECM-Induced
- Matrix Stiffness/Physical Confinement [88]
Cell Signaling-Induced
- Prostate Stromal Cells [120]
- Endothelial Cells [118]
- MSCs [117, 118]
Biochemical-Induced
- Hypoxia [128]
Drug-Induced
- Docetaxel [148]
- Proliferation [118, 148]
- Metabolic Activity [88]
- Morphology [117, 118, 128]
- Chemoresistance [176, 177]
Lung cancer
- A549 [94, 117, 178]
- PC-9 [157]
- H1975 [104]
ECM-Induced
- Physical confinement [94]
- Mechanical forces [104]
Cell Signaling-Induced
- MSCs [117]
- Proliferation [104]
- Cell Cycle Analysis [94]
- Morphology [94, 104, 117]
- Gene/Protein Expression [94, 104, 157, 178]
- Invasion/Motility [94, 104]
- Chemoresistance [94, 104, 157, 178]
Colorectal/Colon Cancer
- DLD-1 [177]
- LoVo [147]
- HCT-116 [89, 128, 147]
- Primary colon cancer cells [147, 177]
ECM-Induced
- Matrix Stiffness/Physical Confinement [89]
Biochemical-Induced
- Hypoxia [128]
- EGF [147]
Drug-Induced
- 5-FU [147]
- Proliferation [147]
- Metabolic Activity [89, 128]
- Viability [89, 177]
- Morphology [89, 128]
- Chemoresistance [89, 128, 177]
Pancreatic Cancer
- PANC-1 [117]
- Capan-1 [176]
- CFPAC [89]
ECM-Induced
- Matrix Stiffness/Physical Confinement [89]
Cell Signaling-Induced
- MSCs [117]
- Proliferation [89]
- Metabolic Activity [89]
- Viability [89]
- Morphology [89, 117]
- Chemoresistance [89, 176]
Other Cancers
- Bladder Cancer (T24, UMUC-3, J82) [120, 176]
- Oral Squamous Cell Carcinoma (SCC-71) [128]
- Osteosarcoma (U2OS, MG63, Saos-2) [58, 128]
- Gastric Cancer (AGS) [176]
- Glioblastoma (U251) [176]
- Ovarian Cancer (OVCAR-5) [88]
ECM-Induced
- Matrix Stiffness/Physical Confinement [88, 128]
Cell Signaling-Induced
- Endothelial Cells [58]
- MSCs [58]
- Osteoblasts [58]
- Prostate Stromal Cells [120]
- Fibroblasts [120]
- Proliferation [58, 128]
- Cell Cycle Analysis [120]
- Metabolic Activity [88, 128]
- Viability [88, 120]
- Chemoresistance [128, 176]
  1. Abbreviations: 5-FU 5-Fluorouracil, ECM Extra-Cellular Matrix, EGF Epidermal Growth Factor, EVs Extracellular Vesicles, FGF-2 Fibroblast Growth Factor-2, MSCs Mesenchymal Stem/Stromal Cells, NPCs Non-Parenchymal Cells